AstraZeneca is investing $2 billion in Summit Therapeutics via convertible preferred stock for about 12% ownership, alongside an alliance to test Summit's ivonescimab with AstraZeneca cancer drugs.
We only link to sources you can read without a subscription. How we check.
Option Care Health agreed to be acquired by private equity firm CD&R and drug distributor McKesson for $32.05 per share in cash. The deal values the home and alternate-site infusion provider at about $5.8 billion. The offer is a roughly 37% premium to Option Care's October 5 closing price.
Medtronic set the final exchange ratio at 4.5939 MiniMed shares per Medtronic share in its exchange offer to split off MiniMed Group.
AmyriAD Therapeutics acquired Recognify and its cognition drug RL-007 in an all-share transaction.
Integrity Care Group acquired 15 NextCare urgent care clinics in Oklahoma, Missouri and Nebraska, reaching 100 locations.